Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NRM004
MIFTS: 50

Neuroma

Categories: Cancer diseases, Neuronal diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Neuroma

About this section

MalaCards integrated aliases for Neuroma:

Name: Neuroma 11 53 43 14 16 71 75

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:2001
MeSH 43 D009463
NCIt 49 C3275
SNOMED-CT 68 443892003
UMLS 71 C0027858
Sources

Summaries for Neuroma

About this section

Disease Ontology: 11 A nervous system benign neoplasm that is characterized as a nerve tissue tumor.

MalaCards based summary: Neuroma is related to neurilemmoma and multiple endocrine neoplasia, type iib. An important gene associated with Neuroma is ANK3 (Ankyrin 3), and among its related pathways/superpathways are Nervous system development and Signal Transduction. The drugs Mepivacaine and Capsaicin have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and dorsal root ganglion, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: 75 A neuroma (/njʊəˈroʊmə/; plural: neuromata or neuromas) is a growth or tumor of nerve tissue. Neuromas... more...
Sources

Related Diseases for Neuroma

About this section

Diseases related to Neuroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 560)
# Related Disease Score Top Affiliating Genes
1 neurilemmoma 32.2 S100B NF2 GFAP ENO2
2 multiple endocrine neoplasia, type iib 32.1 RET GDNF CALCA
3 multiple mucosal neuroma 32.1 RET GDNF CALCA
4 neurofibromatosis, type i 31.7 SOS1 S100B RET NF2 ENO2
5 facial paralysis 31.6 TGFB1 NF2 IL6
6 neurofibroma 31.2 TGFB1 S100B NF2
7 multiple endocrine neoplasia 30.8 RET GDNF CALCA
8 thyroid gland medullary carcinoma 30.7 RET GDNF CALCA
9 trigeminal neuralgia 30.7 SCN10A NGF CALCA
10 thyroid carcinoma, familial medullary 30.7 RET GDNF CALCA
11 meningioma, familial 30.7 S100B RET NF2 MGMT GFAP ENO2
12 sensorineural hearing loss 30.7 SEMA3A RET NGF NF2 FGFR1
13 obstructive hydrocephalus 30.6 NF2 GFAP ENO2
14 hydrocephalus 30.6 TGFB1 S100B NGF GFAP GDNF FGFR1
15 neuritis 30.6 IL6 GFAP GDNF
16 otosclerosis 30.6 TGFB1 NF2 IL6 CALCA
17 brain cancer 30.5 NF2 MGMT GFAP FGF2 ENO2
18 nerve compression syndrome 30.5 NGF IL6 CALCA
19 myoblastoma 30.4 ENO2 CD68
20 brachial plexus lesion 30.4 SEMA3F GDNF
21 multiple endocrine neoplasia, type iia 30.3 RET GDNF CALCA
22 intracranial hypertension 30.3 S100B IL6 GFAP ENO2
23 cellular ependymoma 30.3 S100B NF2 MGMT GFAP
24 hemangioma 30.3 RET IL6 FGF2 ENO2 CALCA
25 meningitis 30.3 S100B IL6 GDNF ENO2 CALCA
26 vascular disease 30.2 TGFB1 IL6 FGFR1 FGF2 CALCA
27 pheochromocytoma 30.2 S100B RET NGF IL6 GDNF FGF2
28 mononeuropathy 30.1 NGF IL6 CALCA
29 keratopathy 30.1 NGF IL6 CALCA
30 pineocytoma 30.1 S100B GFAP ENO2
31 orbital cancer 30.1 NF2 ENO2 CD68
32 neurofibrosarcoma 30.0 NF2 FGFR1 ENO2
33 complex regional pain syndrome 30.0 SCN10A NGF IL6 CALCA
34 paine syndrome 30.0 SCN10A NGF IL6 CALCA
35 tuberous sclerosis 30.0 S100B NF2 GFAP ENO2
36 spinal cord disease 30.0 NF2 MGMT IL6 GFAP GDNF FGFR1
37 low grade glioma 30.0 MGMT GFAP FGFR1
38 encephalomalacia 30.0 S100B IL6 GFAP CD68
39 granular cell tumor 29.9 S100B GFAP ENO2 CD68
40 migraine with or without aura 1 29.9 SCN10A S100B NGF IL6 GFAP CALCA
41 horner's syndrome 29.9 NGF ENO2 CALCA
42 intestinal obstruction 29.9 RET IL6 GDNF
43 causalgia 29.9 SCN10A NGF CALCA
44 hemiplegia 29.9 S100B ENO2 CALCA
45 fibromyalgia 29.8 NGF IL6 CALCA
46 diabetic neuropathy 29.8 SCN10A NGF GDNF CALCA
47 somatoform disorder 29.8 SCN10A NGF IL6 CALCA
48 scoliosis 29.7 TGFB1 IL6 GFAP FGFR1 FGF2
49 epicondylitis 29.7 TGFB1 CALCA
50 thyroid gland cancer 29.6 RET GDNF ENO2 CALCA

Graphical network of the top 20 diseases related to Neuroma:



Diseases related to Neuroma
Sources

Symptoms & Phenotypes for Neuroma

About this section

GenomeRNAi Phenotypes related to Neuroma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 ANK3 BICRA CALCA CD68 ENO2 FGF2
2 no effect GR00402-S-2 10.15 ANK3 CALCA CD68 FGF2 FGFR1 GDNF

MGI Mouse Phenotypes related to Neuroma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.41 ANK3 CALCA ENO2 FGF2 FGFR1 GDNF
2 homeostasis/metabolism MP:0005376 10.25 CALCA FGF2 FGFR1 GFAP IL6 MGMT
3 behavior/neurological MP:0005386 10.16 ANK3 CALCA ENO2 FGF2 FGFR1 GDNF
4 renal/urinary system MP:0005367 10.11 ANK3 CALCA FGFR1 GDNF IL6 NF2
5 no phenotypic analysis MP:0003012 10.1 ANK3 CD68 FGFR1 MGMT NGF RET
6 cardiovascular system MP:0005385 10.1 CALCA FGF2 FGFR1 GDNF GFAP IL6
7 muscle MP:0005369 10.09 FGF2 FGFR1 GDNF GFAP IL6 NGF
8 neoplasm MP:0002006 10.05 CALCA FGF2 IL6 MGMT NF2 RET
9 digestive/alimentary MP:0005381 9.97 FGFR1 GDNF GFAP IL6 NF2 RET
10 mortality/aging MP:0010768 9.86 ANK3 BICRA CALCA FGF2 FGFR1 GDNF
11 respiratory system MP:0005388 9.85 ANK3 CALCA ENO2 IL6 MGMT NF2
12 integument MP:0010771 9.32 CALCA FGFR1 IL6 NF2 NGF S100B
Sources

Drugs & Therapeutics for Neuroma

About this section

Drugs for Neuroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mepivacaine Approved, Vet_approved Phase 4 96-88-8, 1722-62-9 4062
2
Capsaicin Approved Phase 2 404-86-4 1548943
3
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
4
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
5
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
6
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
7
Acetylsalicylic acid Approved, Vet_approved Phase 2 50-78-2 2244
8
Nimodipine Approved, Investigational Phase 2 66085-59-4 4497
9
Losartan Approved Phase 2 114798-26-4 3961
10
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198
11
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
12
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
13 Angiogenesis Inhibitors Phase 2
14 Antineoplastic Agents, Immunological Phase 2
15 Endostatins Phase 2
16 Immunoglobulins, Intravenous Phase 2
17 Immunoglobulins Phase 2
18 Antibodies, Monoclonal Phase 2
19 Antibodies Phase 2
20 Endothelial Growth Factors Phase 2
21 Mitogens Phase 2
22 Hormones Phase 2
23 Analgesics Phase 2
24 Antirheumatic Agents Phase 2
25 Fibrinolytic Agents Phase 2
26 Antipyretics Phase 2
27 Cyclooxygenase Inhibitors Phase 2
28 Platelet Aggregation Inhibitors Phase 2
29 Anti-Inflammatory Agents, Non-Steroidal Phase 2
30 Analgesics, Non-Narcotic Phase 2
31 Vasodilator Agents Phase 2
32 Calcium, Dietary Phase 2
33 calcium channel blockers Phase 2
34 Gelatin Sponge, Absorbable Phase 2
35 Protein Kinase Inhibitors Phase 2
36 Immunosuppressive Agents Phase 2
37 Immunologic Factors Phase 2
38 Anti-Arrhythmia Agents Phase 2
39 Antihypertensive Agents Phase 2
40
Angiotensinogen Phase 2 16133225
41 Angiotensin Receptor Antagonists Phase 2
42 Angiotensin II Type 1 Receptor Blockers Phase 2
43 Giapreza Phase 2
44
Calcium Nutraceutical Phase 2 7440-70-2 271
45
Triamcinolone Approved, Vet_approved Phase 1 124-94-7 31307
46
Nitrous oxide Approved, Vet_approved Phase 1 10024-97-2 948
47
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
48 Dermatologic Agents Phase 1
49 Hormone Antagonists Phase 1
50 glucocorticoids Phase 1

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Comparison Between Blind and Ultrasound Guided Injection in Morton Neuroma Unknown status NCT03046108 Phase 4 blind injection of Mepivacaine;blind injection of Triamcinolone;guided injection of mepivacaine;guided injection of Triamcinolone
2 Pathophysiology of Post Amputation Pain Completed NCT01632709 Phase 4 Bupivacaine;Placebo
3 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With Definite Remaining Vestibular Function Withdrawn NCT02379754 Phase 4 Gentamicins
4 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function Withdrawn NCT02415257 Phase 4 Gentamicin
5 Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma Unknown status NCT01449604 Phase 3
6 Kan tumorvækst Forudsiges Ved RGD-PET/MR af Vestibularis Schwannomer? Unknown status NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
7 An Open-Label, Multiple-Dose Extension Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02678793 Phase 2 CNTX-4975
8 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02283957 Phase 2 CNTX-4975
9 A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma Completed NCT00130962 Phase 2 ALGRX 4975
10 Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping Completed NCT02104323 Phase 2 Endostatin
11 Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Completed NCT02129647 Phase 2 Axitinib
12 Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors Completed NCT00973739 Phase 2 Lapatinib
13 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
14 Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma Completed NCT01207687 Phase 2
15 Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation Completed NCT01767792 Phase 2 Bevacizumab
16 A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Completed NCT01490476 Phase 2 RAD001
17 Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02934256 Phase 2 Icotinib
18 Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas Recruiting NCT03079999 Phase 2 Aspirin;Placebo
19 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
20 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
21 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Recruiting NCT04351373 Phase 2 intravenous fluorescein sodium
22 Intraoperative Application of Nimodipine to the Facial and Cochlear Nerves During Vestibular Schwannoma Resection to Avoid Spasm-related Postoperative Facial Paralysis and Deafness - a Prospective Randomized Pilot Study Recruiting NCT04801953 Phase 2 NiMODipine Injectable Solution
23 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Active, not recruiting NCT01199978 Phase 2 Losartan
24 A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
25 Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT04283669 Phase 2 Crizotinib
26 A Phase II Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
27 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial of Botulinum Toxin Type A for Neuroma Pain Withdrawn NCT01374191 Phase 2 onabotulinum toxin type-A;2nd phase - onabotulinum toxin type-A
28 An Open Label, Ascending Dose Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02550756 Phase 1 CTNX-4975
29 A 3-arm Randomized Controlled Study Comparing Ultrasound-guided Cryoablation, Ultrasound-guided Perineural Lidocaine and Ultrasound-guided Perineural Saline to Treat Intermetatarsal Neuroma Completed NCT02838758 Phase 1 Lidocaine;Saline
30 Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas Completed NCT04658836 Phase 1 Triamcinolone Acetonide 40mg/mL
31 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
32 Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma (Acoustic Neuroma) Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
33 Impact of Shared Decision-Making With Decision Aids on Acoustic Neuroma Treatment Choice: A Randomized Controlled Trial Unknown status NCT04101409
34 A Randomised Controlled Trial to Compare the Clinical Effectiveness of Lower Extremity Manipulation to That of Steroid Injection in the Treatment of Morton's Neuroma Unknown status NCT02304094 methylprednisolone
35 Acoustic Neuroma: Assessing the Quality of Life by the Scale PANQOL of Patients Operated or Supervised Unknown status NCT04004377
36 Comparison of Corticosteroid and Ethanol Injection Therapy in the Treatment of Morton's Neuroma Unknown status NCT00284583 Injection of Steroid into Foot;Injection of Alcohol into Foot;Injection of Lidocaine into Foot
37 Clinical and Radiological Evaluation of Acoustic Neuromas With Spontaneous Shrinkage Unknown status NCT03970681
38 Novel Multimodality Imaging Techniques for Neurosurgical Planning and Stereotactic Navigation in Lateral Skull Base Surgery: a Feasibility Study Unknown status NCT04128345
39 Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base Unknown status NCT04249921
40 The Impact of Vestibular Rehabilitation on the Longitudinal Recovery of Laboratory, Clinical, and Community-Based Measures of Head and Trunk Control in People With Acquired Vestibulopathy Unknown status NCT04594057
41 Assessment of the Preoperative Vestibular Rehabilitation Effectiveness on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT02275325
42 Response Prediction After Gamma Knife Surgery (GKS) in Patients With Vestibular Schwannoma Using Dynamic Contrast-Enhanced (DCE) MR Imaging Unknown status NCT03097822
43 Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI Unknown status NCT03593577
44 Consequence of Unilateral Vestibular Loss on Visual Abilities Unknown status NCT03581331
45 Focused Ultrasound Treatment of Stump Neuromas for the Relief of Chronic Post-Amputation Neuropathic Pain Unknown status NCT03255395
46 NF2 Natural History Consortium Unknown status NCT00004483
47 Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery Unknown status NCT03520829
48 Evaluation of Endoscopic-assisted Microsurgical Removal of Cerebellopontine Angle Lesions Unknown status NCT03228511
49 Evaluation of the Influence of Psychological Factors on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT01743248
50 The Presence and Role of Zygomatic-temporal Neuroma Triggering Cluster Headache: Resection of a Neuroma in the Long-term Resolution of Trigeminal Cluster Symptoms Completed NCT04845451

Search NIH Clinical Center for Neuroma

Cochrane evidence based reviews: neuroma

Sources

Genetic Tests for Neuroma

About this section
Sources

Anatomical Context for Neuroma

About this section

Organs/tissues related to Neuroma:

MalaCards : Brain, Spinal Cord, Dorsal Root Ganglion, Bone, Endothelial, Appendix, Bone Marrow
Sources

Publications for Neuroma

About this section

Articles related to Neuroma:

(show top 50) (show all 5728)
# Title Authors PMID Year
1
Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. 53 62
19150372 2009
2
Vanilloid receptor 1 (TRPV1) expression in lingual nerve neuromas from patients with or without symptoms of burning pain. 53 62
17109831 2007
3
Elevated ankyrin G in a plexiform neurofibroma and neuromas associated with pain. 53 62
15519868 2004
4
Painful neuromas: a potential role for a structural transmembrane protein, ankyrin G. 53 62
12507143 2002
5
Ankyrin G and voltage gated sodium channels colocalize in human neuroma--key proteins of membrane remodeling after axonal injury. 53 62
11950515 2002
6
Receptors for NGF and GDNF are highly expressed in human peripheral nerve neuroma. 53 62
11932982 2002
7
Calcitonin gene-related peptide modifies the ectopic discharge from damaged nerve fibres in the ferret. 53 62
11207377 2001
8
Peptides and neuromas: calcitonin gene-related peptide, substance P, and mast cells in a mechanosensitive human sural neuroma. 53 62
9179160 1997
9
Evidence for CGRP accumulation and activity in experimental neuromas. 53 62
7864183 1995
10
Regenerative peripheral nerve interface prevents neuroma formation after peripheral nerve transection. 62
36204848 2023
11
A decellularized nerve matrix scaffold inhibits neuroma formation in the stumps of transected peripheral nerve after peripheral nerve injury. 62
36018192 2023
12
Treatment of Morton's neuroma with minimally invasive distal metatarsal metaphyseal osteotomy (DMMO) and percutaneous release of the deep transverse metatarsal ligament (DTML): a case series with minimum two-year follow-up. 62
36031662 2022
13
Hilar Biliary Amputation Neuroma Following Liver Transplant: A Case Report and Review of the Literature for this Diagnostic and Therapeutic Challenge. 62
36382132 2022
14
Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. 62
35726101 2022
15
A Cohort Study on Neuropathic Pain of the Sural Nerve-Can Neurectomy Be Considered a Valid Treatment Option? 62
36416695 2022
16
A Method for Entubulating Exposed Nerve Ends Following Neurectomy Using a Porcine Extracellular Matrix Nerve Cap. 62
35778874 2022
17
Use of a Novel Clinical Decision-Making Tool in Vestibular Schwannoma Treatment. 62
36240736 2022
18
Musical therapy attenuates neuroma pain by modifying leptin expression. 62
36456983 2022
19
Feasibility of Magnetic Resonance-Guided High-Intensity-Focused Ultrasound (MRgHIFU) Ablation of Stump Neuromas for the Relief of Chronic Postamputation Neuropathic Pain. 62
35633227 2022
20
Assessing Surgical Approaches for Acoustic Neuroma Resection: Do Patients Perceive a Difference in Quality-of-Life Outcomes? 62
36351229 2022
21
Traumatic peripheral nerve injuries: diagnosis and management. 62
36367041 2022
22
Rare malignant melanotic nerve sheath tumors of the upper limb nerves: utility of high-frequency ultrasonography in preoperative imaging. 62
35482066 2022
23
Finger injuries by eyebrow razor blades in infants. 62
36336263 2022
24
A modified three-incision approach to treating three-column Lisfranc injuries. 62
35985903 2022
25
Nerve-End Capping Treatment with a Polyglycolic Acid Conduit for Rat Sciatic Neuroma: A Preliminary Report. 62
36122572 2022
26
Tender Nasal Traumatic (TNT) Neuroma: Case Report and Review. 62
36465207 2022
27
Development of an acellular nerve cap xenograft for neuroma prevention. 62
36082974 2022
28
Venipuncture-related traumatic neuroma of the ulnar nerve on the dorsal of a hand: A case report. 62
36287020 2022
29
"Targeted Muscle Reinnervation for treatment of post-resection Interdigital Neuroma: A Cadaveric Feasibility Study". 62
36219864 2022
30
Plantar and dorsal approaches for excision of morton's neuroma: a comparison study. 62
36203146 2022
31
Painful total knee arthroplasty: Infrapatellar branch of the saphenous nerve selective denervation. A case series. 62
36209652 2022
32
The effect of a gap concept on peripheral nerve recovery in modified epineurial neurorrhaphy: An experimental study in rats. 62
35388916 2022
33
Surgical Treatment of Peripheral Nerve Neuromas: A Systematic Review and Meta-Analysis. 62
35895004 2022
34
Comparing Patient Satisfaction After Upfront Treatment Versus Wait-and-Scan for Small Sporadic Vestibular Schwannoma. 62
36240733 2022
35
Spinal intramedullary cavernous angioma patient in a pain clinic - A case report. 62
35378569 2022
36
Microsurgical Management of Vestibular Schwannoma (Acoustic Neuroma): Facial Nerve Outcomes, Radiographic Analysis, Complications, and Long-Term Follow-Up in a Series of 420 Surgeries. 62
36198364 2022
37
C11 choline PET/CT succeeds when conventional imaging for primary hyperparathyroidism fails. 62
36229257 2022
38
Sensory nerve regeneration and reinnervation in muscle following peripheral nerve injury. 62
35779064 2022
39
Outcomes of bipedicle V-Y 'cup' flap for repair of volar oblique fingertip amputations. 62
36205049 2022
40
Intermetatarsal ligament section assisted with sonography for the percutaneous surgery of Morton's disease: Cadaveric study. 62
35331653 2022
41
Local Environment Induces Differential Gene Expression in Regenerating Nerves. 62
35618492 2022
42
Surgical Treatment Strategies for Injuries of the "Unforgiving" Superficial Branch of the Radial Nerve. 62
35921646 2022
43
A Technical Guide for Sciatic Nerve Targeted Muscle Reinnervation in a Transfemoral Amputee. 62
36187281 2022
44
Primary Targeted Muscle Reinnervation after Below-Knee Amputation Is Not Associated with an Increased Risk of Major or Minor Surgical Complications: A Multi-Institutional, Propensity Score-Matched Analysis. 62
35791757 2022
45
Thinking Out of the Box: Use of the Radial Artery Distally to the Snuffbox as Recipient Vessel. 62
36203735 2022
46
Targeted muscle reinnervation: A narrative review of a novel tool for the management of neuropathic pathology in major lower extremity amputations. 62
36062583 2022
47
Nuances in transcanal endoscopic approach to benign middle ear tumours in adult patients. 62
36031112 2022
48
Multiple Cutaneous Solitary Circumscribed Neuroma in a Patient with Neurofibromatosis Type 2: An "Incidentaloma" or New Association? 62
36128789 2022
49
Tender Cutaneous Neoplasms: Case Reports of Patients With a Symptomatic Dermatofibroma and a New Acrostic for Painful Tumors of the Skin. 62
36321023 2022
50
Characteristics of the ocular surface in neurotrophic keratitis induced by trigeminal nerve injury following neurosurgery. 62
36115903 2022
Sources

Variations for Neuroma

About this section
Sources

Expression for Neuroma

About this section
Search GEO for disease gene expression data for Neuroma.
Sources

Pathways for Neuroma

About this section

Pathways related to Neuroma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Nervous system development 66
Show member pathways
 13.64 TGFB1 SOS1 SEMA3A SCN10A RET GDNF
2
Signal Transduction 66
13.51 TGFB1 SOS1 S100B RET NGF NF2
3
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.49 FGF2 FGFR1 IL6 NGF SCN10A SEMA3A
4
Akt Signaling 64
Show member pathways
 13.35 FGF2 FGFR1 IL6 NGF SEMA3A SOS1
5
RAF/MAP kinase cascade 66
Show member pathways
 13.31 TGFB1 SOS1 RET IL6 GDNF FGFR1
6
CREB Pathway 64
Show member pathways
 13.26 TGFB1 SOS1 SEMA3A NGF IL6 FGFR1
7
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.2 FGF2 FGFR1 IL6 NGF SEMA3A SOS1
8
Phospholipase-C Pathway 64
Show member pathways
 12.98 TGFB1 SOS1 SEMA3A NGF IL6 FGFR1
9
p70S6K Signaling 64
Show member pathways
 12.95 FGF2 FGFR1 IL6 NGF SEMA3A SOS1
10
Signaling by Receptor Tyrosine Kinases 66
12.75 SOS1 S100B NGF GFAP FGFR1 FGF2
11
NF-KappaB Family Pathway 64
Show member pathways
 12.59 TGFB1 SEMA3A NGF IL6 FGFR1 FGF2
12
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.56 TGFB1 SEMA3A NGF IL6 FGFR1 FGF2
13
Malignant pleural mesothelioma 74
12.41 FGF2 FGFR1 IL6 NF2 NGF SOS1
14
MAPK signaling pathway 74
12.33 TGFB1 SOS1 NGF FGFR1 FGF2
15
Toll Comparative Pathway 64
Show member pathways
 12.26 SOS1 IL6 FGFR1 FGF2
16
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.2 TGFB1 SOS1 SEMA3A NGF IL6 FGFR1
17
Neuroscience 3
12.09 SCN10A S100B RET NGF NF2 GFAP
18
Neuroinflammation and glutamatergic signaling 74
11.95 FGF2 GFAP IL6 NGF TGFB1
19
Spinal cord injury 74
11.93 GDNF GFAP IL6 TGFB1
20
NCAM signaling for neurite out-growth 66
Show member pathways
 11.88 SOS1 GDNF FGFR1
21
Neural crest differentiation 74
11.86 GFAP FGFR1 FGF2
22
CCL18 signaling pathway 74
11.84 TGFB1 IL6 FGF2
23
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.83 TGFB1 IL6 FGF2
24
FGFR1 mutant receptor activation 66
Show member pathways
 11.8 SOS1 FGFR1 FGF2
25
Angiogenesis (CST) 3
11.79 TGFB1 FGFR1 FGF2
26
RET signaling 66
Show member pathways
 11.72 SOS1 RET GDNF
27
Burn wound healing 74
11.7 TGFB1 IL6 FGFR1
28
Acute viral myocarditis 74
11.7 TGFB1 SOS1 IL6
29
Clock-controlled autophagy in bone metabolism 74
11.68 TGFB1 SEMA3A IL6 CALCA
30
Lung fibrosis 74
11.56 TGFB1 IL6 FGF2 CALCA
31
Hepatitis C and hepatocellular carcinoma 74
11.54 TGFB1 SOS1 IL6
32
SHP2 signaling 61
11.53 SOS1 NGF IL6
33
Cell adhesion_Plasmin signaling 22
11.47 TGFB1 FGFR1 FGF2
34
Pluripotent stem cell differentiation pathway 74
11.46 TGFB1 IL6 FGF2
35
Vemurafenib Pathway, Pharmacodynamics 60
11.4 SOS1 FGFR1 FGF2
36
G-protein signaling_RhoA regulation pathway 22
11.39 TGFB1 SOS1 SEMA3A NGF IL6 FGFR1
37
G-protein signaling_H-RAS regulation pathway 22
11.33 SOS1 RET GDNF
38
Neural Stem Cells and Lineage-specific Markers 65
11 S100B NGF GFAP GDNF FGFR1 FGF2
39
Glypican 1 network 61
10.97 TGFB1 FGFR1 FGF2
40
G-protein signaling_Rap2B regulation pathway 22
10.88 TGFB1 SEMA3A NGF IL6 GFAP FGFR1
41
IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
10.75 TGFB1 IL6
Sources

GO Terms for Neuroma

About this section

Cellular components related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.16 TGFB1 SEMA3F SEMA3A S100B NGF IL6
2 neuronal cell body GO:0043025 9.65 CALCA ENO2 RET S100B SOS1 TGFB1
3 axon GO:0030424 9.36 TGFB1 SEMA3A SCN10A RET NGF CALCA

Biological processes related to Neuroma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.35 TGFB1 RET NGF IL6 FGF2 ANK3
2 aging GO:0007568 10.12 TGFB1 FGF2 CD68 CALCA
3 MAPK cascade GO:0000165 10.08 TGFB1 RET NF2 FGFR1
4 positive regulation of cell population proliferation GO:0008284 10.07 BICRA FGF2 FGFR1 GDNF IL6 S100B
5 positive regulation of protein kinase B signaling GO:0051897 10.02 FGF2 FGFR1 RET TGFB1
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.91 TGFB1 FGFR1 FGF2
7 neural crest cell migration involved in autonomic nervous system development GO:1901166 9.85 SEMA3A SEMA3F
8 ureteric bud development GO:0001657 9.8 TGFB1 RET GDNF
9 positive regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000546 9.76 FGFR1 FGF2
10 semaphorin-plexin signaling pathway involved in neuron projection guidance GO:1902285 9.73 SEMA3F SEMA3A
11 sympathetic neuron projection guidance GO:0097491 9.71 SEMA3F SEMA3A
12 positive regulation of receptor signaling pathway via STAT GO:1904894 9.7 TGFB1 IL6
13 sympathetic neuron projection extension GO:0097490 9.67 SEMA3F SEMA3A
14 nerve development GO:0021675 9.63 SEMA3F SEMA3A NGF
15 Schwann cell proliferation GO:0014010 9.62 NF2 GFAP
16 positive regulation of miRNA maturation GO:1903800 9.56 TGFB1 IL6
17 neural crest cell migration GO:0001755 9.23 SEMA3F SEMA3A RET GDNF
18 system development GO:0048731 9.13 SEMA3F GDNF FGF2

Molecular functions related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.32 TGFB1 NGF IL6 GDNF FGF2
2 receptor-receptor interaction GO:0090722 9.26 FGFR1 FGF2
Sources

Sources for Neuroma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....